Bionexus Gene Lab Corp (BGLC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2018 | |
| Cash Flows From Operating Activities | |
| Net Income | 272 |
| Depreciation Amortization | 11 |
| Accounts receivable | 114 |
| Accounts payable and accrued liabilities | -1,061 |
| Other Working Capital | -956 |
| Other Operating Activity | 947 |
| Operating Cash Flow | $-674 |
| Cash Flows From Investing Activities | |
| PPE Investments | -17 |
| Purchase Of Investment | -13 |
| Investing Cash Flow | $-30 |
| Cash Flows From Financing Activities | |
| Common Stock Issued | 1,115 |
| Other Financing Activity | 1 |
| Financing Cash Flow | $1,117 |
| Exchange Rate Effect | -28 |
| Beginning Cash Position | 839 |
| End Cash Position | 1,225 |
| Net Cash Flow | $385 |
| Free Cash Flow | |
| Operating Cash Flow | -674 |
| Capital Expenditure | -17 |
| Free Cash Flow | -691 |